The following article requires a subscription:



(Format: HTML, PDF)

: Type-2-cell-mediated immunity, rich in eosinophils, basophils, mast cells, CD4 T helper 2 (Th2) cells, and type 2 innate lymphoid cells (ILC2s), protects the host from helminth infection but also drives chronic allergic diseases like asthma and atopic dermatitis. Barrier epithelial cells (ECs) represent the very first line of defense and express pattern recognition receptors to recognize type-2-cell-mediated immune insults like proteolytic allergens or helminths. These ECs mount a prototypical response made up of chemokines, innate cytokines such as interleukin-1 (IL-1), IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), as well as the alarmins uric acid, ATP, HMGB1, and S100 proteins. These signals program dendritic cells (DCs) to mount Th2-cell-mediated immunity and in so doing boost ILC2, basophil, and mast cell function. Here we review the general mechanisms of how different stimuli trigger type-2-cell-mediated immunity at mucosal barriers and how this leads to protection or disease.

: Although the role of hematopoietic cell subsets in initiating and maintaining a type 2 immune response has been extensively studied, the contribution of non-hematopoietic cells to this biology has only recently been appreciated. Hammad and Lambrecht review the literature on the specific role of barrier epithelial cells in this signature immune response.

(C) 2015Elsevier, Inc.